Nivolumab Provides Durable Response in dMMR/MSI-H Colorectal Cancer

Share this content:
The Checkmate-142 trial enrolled 74 patients with previously treated dMMR/MSI-H colorectal cancer to receive nivolumab 3 mg/kg every 2 weeks.
The Checkmate-142 trial enrolled 74 patients with previously treated dMMR/MSI-H colorectal cancer to receive nivolumab 3 mg/kg every 2 weeks.

Nivolumab demonstrated durable disease control and responses in patients with metastatic DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer who failed prior therapy, according to a study published in The Lancet Oncology.1

dMMR/MSI-H colorectal cancer is associated with higher tumor neoantigen load, mutational burdens, dense immune cell infiltration, and distinct biomarkers, features that are associated with a clinical response to immune checkpoint inhibitors in other tumor types.

For the Checkmate-142 trial (ClinicalTrials.gov Identifier: NCT02060188), researchers enrolled 74 patients with previously treated dMMR/MSI-H colorectal cancer to receive nivolumab 3 mg/kg every 2 weeks.

Out of 74 patients, 23 (31.1%; 95% CI, 20.8-42.9) patients achieved an objective response as per investigator assessment at the median follow-up of 12 months.

At 12 weeks, disease control was achieved in 51 (69%; 95% CI, 57-69) patients.

RELATED: FOLFOXIRI Plus Bev May Improve Outcomes in Colorectal Cancer

Treatment related adverse events (AEs) occurred in 70% of enrolled patients, and 20% of patients experienced grade 3 or 4 AEs. The most frequently reported grade 3 or 4 AEs were increased lipase and increased amylase.

None of the 23 deaths that occurred during the study were deemed treatment-related.

Reference

  1. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017 Jul 19. doi: 10.1016/S1470-2045(17)30422-9 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters